MCID: HDR002
MIFTS: 55

Hidradenitis Suppurativa

Categories: Rare diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Hidradenitis Suppurativa

MalaCards integrated aliases for Hidradenitis Suppurativa:

Name: Hidradenitis Suppurativa 11 19 42 75 41 43 14 16 71 31 33
Acne Inversa 19 42 38 33
Suppurative Hidradenitis 42 33
Hidradenitides, Suppurative 42
Suppurative Hidradenitides 42
Hidradenitis, Suppurative 42
Acne Inversa, Familial 11
Inverse Acne 33
Apocrinitis 42

Classifications:



External Ids:

Disease Ontology 11 DOID:2280
MeSH 43 D017497
NCIt 49 C128429
SNOMED-CT 68 201204008
ICD10 31 L73.2
ICD11 33 1621794154
UMLS 71 C0162836

Summaries for Hidradenitis Suppurativa

MedlinePlus: 41 What is hidradenitis suppurativa (HS)? Hidradenitis suppurativa (HS) is a chronic skin disease. It causes painful, boil-like lumps that form under the skin. It often affects areas where the skin rubs together, such as your armpits and groin. The lumps become inflamed and painful. They often break open, causing abscesses that drain fluid and pus. As the abscesses heal, they can cause scarring of the skin. What causes hidradenitis suppurativa (HS)? The lumps in HS form because of blockages of the hair follicles. The blocked hair follicles trap bacteria, which leads to inflammation and rupture. In most cases, the cause of the blockages is unknown. Genetics, environment, and hormonal factors may play a role. Some cases of HS are caused by changes in certain genes. HS is not caused by bad hygiene, and it cannot be spread to others. Who is at risk for hidradenitis suppurativa (HS)? HS usually starts after puberty, usually in the teens or twenties. It is more common in: Women People with a family history of HS People who are overweight or have obesity Smokers What are the symptoms of hidradenitis suppurativa (HS)? The symptoms of HS include: Small pitted areas of skin containing blackheads Painful, red, lumps that get bigger and break open. This causes abscesses that drain fluid and pus. They may itch and have an unpleasant odor. The abscesses heal very slowly, recur over time, and can lead to scarring and tunnels under the skin HS can be mild, moderate, or severe: In mild HS, there are only one or a few lumps in one area of the skin. A mild case will often get worse, becoming a moderate disease. Moderate HS include recurrences of the lumps that get bigger and break open. The lumps form in more than one area of the body. With severe HS, there are widespread lumps, scarring, and chronic pain that may make it hard to move Because of the difficulty of dealing with the disease, people with HS are at risk for depression and anxiety. How is hidradenitis suppurativa (HS) diagnosed? There is no specific test for HS, and it is often misdiagnosed in the early stages. To make a diagnosis, your health care provider will ask about your medical history and your symptoms. He or she will look at the lumps on your skin and test a sample of the skin or pus (if there is any). What are the treatments for hidradenitis suppurativa? There is no cure for HS. Treatments focus on the symptoms, but they are not always effective for everyone. The treatments depend on how severe the disease is, and they include: Medicines, including steroids, antibiotics, pain relievers, and medicines that flight inflammation. In mild cases, the medicines may be topical. This means that you apply them to your skin. Otherwise the medicines may be injected or taken orally (by mouth). Surgery for severe cases, to remove the lumps and scars It may also help if you can avoid things that can irritate your skin, by: Wearing loose-fitting clothing Staying at a healthy weight Quitting smoking Avoiding heat and humidity Being careful not to injure your skin

MalaCards based summary: Hidradenitis Suppurativa, also known as acne inversa, is related to dowling-degos disease and inflammatory bowel disease 1, and has symptoms including painful nodules, pruritus and exanthema. An important gene associated with Hidradenitis Suppurativa is NCSTN (Nicastrin), and among its related pathways/superpathways are ERK Signaling and Disease. The drugs Triamcinolone and Anesthetics have been mentioned in the context of this disorder. Affiliated tissues include skin, liver and lymph node, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and immune system

GARD: 19 Hidradenitis suppurativa (HS) is a chronic skin disease which causes painful, boil-like lumps that form under the skin and often secrete pus and blood. HS occurs most often in areas where skin rubs together, such as the armpits, groin, and under the breasts. Symptoms usually begin after puberty. The first sign may be a single pocket of pus (abscess) or hard lumps associated with hair follicles. The abscesses or lumps often change to painful swollen clusters of skin sores that drain a bloody and often, bad smelling discharge. As the sores heal, they may leave hardened, rope-like scars or form tunnels under the skin (called sinus tracks) that can be disfiguring and make movement difficult. As time goes by, the skin lesions occur more often and get worse over time. In most cases, the cause of HS is unknown. Genetics, environment, and hormonal factors may play a role. Some cases of HS have been associated with specific genes, including NCSTN, PSEN1, and PSENEN. Diagnosis of HS is made based on the clinical symptoms.

MedlinePlus Genetics: 42 Hidradenitis suppurativa, also known as acne inversa, is a chronic skin disease characterized by recurrent boil-like lumps (nodules) under the skin. The nodules become inflamed and painful. They tend to break open (rupture), causing abscesses that drain fluid and pus. As the abscesses heal, they produce significant scarring of the skin.The signs and symptoms of hidradenitis suppurativa typically appear after puberty, usually in a person's teens or twenties, although they can begin earlier in puberty, particularly in affected females. Nodules are most likely to form in the armpits and groin. They may also develop around the anus, on the buttocks, or under the breasts. In some cases, nodules appear in other areas, such as the nape of the neck, waist, and inner thighs.The recurrent nodules and abscesses cause chronic pain and can lead to self-consciousness, social isolation, and depression. Rarely, long-term (chronic) abscesses on the buttocks can develop into a type of skin cancer called squamous cell carcinoma.

Disease Ontology: 11 A hidradenitis that is characterized by chronic inflammation of the apocrine sweat glands, has symptom painful nodules, abscesses, sinus tract formation, scarring, erythema, pruritis, and pain, and has material basis in chronic inflammation of the apocrine sweat glands leading to recurrent folliculitis and an accompanying immune response that worsens inflammation.

Wikipedia: 75 Hidradenitis suppurativa (HS), sometimes known as acne inversa or Verneuil's disease, is a long-term... more...

Related Diseases for Hidradenitis Suppurativa

Diseases related to Hidradenitis Suppurativa via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 860)
# Related Disease Score Top Affiliating Genes
1 dowling-degos disease 31.5 PSENEN PSEN1 NCSTN
2 inflammatory bowel disease 1 31.4 TNF NOD2 IL1B IL17A
3 folliculitis 31.4 TNF IL17A IFNG
4 spondyloarthropathy 1 31.3 TNF NOD2 IL1B IL17A CRP
5 pyoderma gangrenosum 31.2 TNF PSTPIP1 NOD2 NLRP3 MEFV IL1B
6 bowel dysfunction 31.1 TNF NOD2 LCN2 IL1B CRP
7 cellulitis 31.1 TNF IL1B IL17A CRP CAMP
8 chronic ulcer of skin 31.0 TNF IL1B CRP
9 serum amyloid a amyloidosis 31.0 TNF NLRP3 MEFV CRP
10 synovitis 30.9 TNF IL1B IL1A CRP
11 sapho syndrome 30.9 TNF PSTPIP1 NOD2 IL17A CRP
12 reactive arthritis 30.9 TNF IL17A CRP
13 pyoderma 30.9 TNF PSTPIP1 NOD2 NLRP3 MEFV IL1B
14 alopecia 30.9 TNF IL1B IL1A IL17A IFNG
15 arthropathy 30.9 TNF NOD2 NLRP3 IL1B CRP
16 acne 30.9 TNF S100A7 PSTPIP1 PSENEN PSEN1 NLRP3
17 amyloidosis 30.9 TNF PSEN1 NLRP3 MEFV IL1B CRP
18 crohn's disease 30.9 TNF NOD2 NLRP3 IL26 IL1B IL17A
19 autoinflammatory syndrome 30.8 NOD2 NLRP3 MEFV
20 keratitis, hereditary 30.8 TNF NLRP3 IL1B IL17A GJB2
21 covid-19 30.8 TNF NLRP3 IL1B CRP
22 seborrheic dermatitis 30.8 TNF IL1A IL17A
23 osteoarthritis 30.8 TNF IL1B IL1A IL17A CRP
24 substance abuse 30.8 TNF IL1B CRP
25 apnea, obstructive sleep 30.7 TNF IL1B CRP
26 fibromyalgia 30.7 TNF IL1B CRP
27 alopecia areata 30.7 TNF IL1B IL1A IL17A IFNG
28 rosacea 30.7 TNF IL1B IL17A CRP CAMP
29 histiocytosis 30.7 TNF IL17A IFNG
30 irritable bowel syndrome 30.6 TNF IL1B IL17A CRP
31 dermatitis 30.6 TNF S100A7 NOD2 NLRP3 IL1B IL1A
32 anal canal squamous cell carcinoma 30.6 PSENEN NCSTN
33 alcohol use disorder 30.6 TNF IL1B CRP
34 fatty liver disease 30.6 TNF IL1B IL1A CRP
35 sleep disorder 30.6 TNF IL1B CRP
36 scleritis 30.5 TNF IFNG CRP
37 interstitial keratitis 30.5 TNF CRP
38 lymphangioma 30.5 TNF IL1B IL17A IFNG
39 brucellosis 30.5 TNF NLRP3 MEFV IL17A IFNG CRP
40 pustulosis of palm and sole 30.5 TNF PSTPIP1 IL17A CRP
41 ulcerative colitis 30.5 TNF NOD2 IL23A IL1B IL17A IFNG
42 psoriasis 30.5 TNF S100A7 NOD2 IL23A IL1B IL1A
43 necrotizing fasciitis 30.5 TNF IL1B CRP CAMP
44 disease of mental health 30.5 TNF PSEN1 IL1B CRP
45 nephrotic syndrome 30.5 TNF LCN2 IL1B IL17A CRP
46 keratoconjunctivitis 30.4 TNF IL1A IFNG
47 uveitis 30.4 TNF NOD2 IL1B IL1A IL17A IFNG
48 melkersson-rosenthal syndrome 30.4 TNF NOD2 CRP
49 pemphigoid 30.4 TNF IL1B IL17A IFNG
50 aortic atherosclerosis 30.4 TNF IL1B CRP

Graphical network of the top 20 diseases related to Hidradenitis Suppurativa:



Diseases related to Hidradenitis Suppurativa

Symptoms & Phenotypes for Hidradenitis Suppurativa

Symptoms:

11
  • painful nodules

UMLS symptoms related to Hidradenitis Suppurativa:


pruritus; exanthema

GenomeRNAi Phenotypes related to Hidradenitis Suppurativa according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.18 CAMP CRP GJB2 IFNG IL12RB1 IL17A
2 no effect GR00402-S-2 10.18 CAMP CRP IFNG IL12RB1 IL1A IL1B
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 10.07 IL17A IL1A IL1B LCN2 NLRP3 TNF
4 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 10.07 IL17A IL1B LCN2 NLRP3 NOD2 PSEN1

MGI Mouse Phenotypes related to Hidradenitis Suppurativa:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.25 CAMP CRP GJB2 IFNG IL12RB1 IL17A
2 homeostasis/metabolism MP:0005376 10.24 CRP GJB2 IFNG IL12RB1 IL17A IL1A
3 hematopoietic system MP:0005397 10.03 CAMP IFNG IL12RB1 IL17A IL1A IL1B
4 skeleton MP:0005390 9.96 GJB2 IFNG IL17A IL1B MEFV NLRP3
5 no phenotypic analysis MP:0003012 9.95 GJB2 IFNG IL17A IL23A LCN2 PSTPIP1
6 mortality/aging MP:0010768 9.8 CAMP GJB2 IFNG IL17A IL1B IL23A
7 integument MP:0010771 9.4 GJB2 IFNG IL12RB1 IL17A IL1A IL1B

Drugs & Therapeutics for Hidradenitis Suppurativa

Drugs for Hidradenitis Suppurativa (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 88)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
2 Anesthetics Phase 4
3
Triamcinolone hexacetonide Phase 4
4
Triamcinolone diacetate Phase 4
5
Triamcinolone Acetonide Phase 4 6436
6 glucocorticoids Phase 4
7 Immunologic Factors Phase 4
8 Immunosuppressive Agents Phase 4
9
Metformin Approved Phase 3 1115-70-4, 657-24-9 4091
10
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
11 Hypoglycemic Agents Phase 3
12 Anti-Bacterial Agents Phase 3
13 Antibiotics, Antitubercular Phase 3
14
Apremilast Approved, Investigational Phase 2 608141-41-9 10151715 11561674
15
Hydroxychloroquine Approved Phase 1, Phase 2 118-42-3 3652
16
Infliximab Approved Phase 2 170277-31-3
17
Ustekinumab Approved, Investigational Phase 2 815610-63-0
18
Etanercept Approved, Investigational Phase 2 185243-69-0
19
Upadacitinib Approved, Investigational Phase 2 1310726-60-3 76829165 58557659
20
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
21
Tannic acid Approved Phase 2 1401-55-4 16129878 16129778
22
Tofacitinib Approved, Investigational Phase 2 477600-75-2 9926791
23
Methylene blue Approved, Investigational Phase 2 61-73-4 6099
24
Gentian violet cation Approved Phase 2 14426-25-6, 7438-46-2 3468 11057
25
Glycerin Approved, Investigational Phase 2 56-81-5 753
26
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
27
Ethinylestradiol Approved Phase 2 57-63-6 5991
28
Polyestradiol phosphate Approved Phase 2 28014-46-2
29
Drospirenone Approved Phase 2 67392-87-4 68873
30
Glutamic acid Approved, Nutraceutical Phase 2 56-86-0 33032
31
Lysine Approved, Nutraceutical Phase 2 56-87-1 5962
32
PF-06700841 Investigational Phase 2 1883299-62-4 118878093
33
Vilobelimab Investigational Phase 2 2250440-41-4
34 Complement System Proteins Phase 2
35 Analgesics Phase 2
36 Phosphodiesterase Inhibitors Phase 2
37 Phosphodiesterase 4 Inhibitors Phase 2
38 Anti-Inflammatory Agents, Non-Steroidal Phase 2
39 Analgesics, Non-Narcotic Phase 2
40 Antiprotozoal Agents Phase 1, Phase 2
41 Antiparasitic Agents Phase 1, Phase 2
42 Antimalarials Phase 1, Phase 2
43 Gastrointestinal Agents Phase 2
44 Interleukin 1 Receptor Antagonist Protein Phase 2
45 Protein Kinase Inhibitors Phase 2
46 Janus Kinase Inhibitors Phase 2
47 interferons Phase 2
48 Immunoglobulins Phase 2
49 Antibodies, Monoclonal Phase 2
50 Antibodies Phase 2

Interventional clinical trials:

(show top 50) (show all 152)
# Name Status NCT ID Phase Drugs
1 Cost-effectiveness of Adalimumab With Adjuvant Surgery Versus Adalimumab Monotherapy in the Treatment of Hidradenitis Suppurativa' Unknown status NCT03221621 Phase 4 Adalimumab Injection
2 A Phase 4, Double-blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Adalimumab Used in Conjunction With Surgery in Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT02808975 Phase 4 Placebo;Adalimumab
3 A Randomized, Controlled Trial Comparing the Use of a Biodegradable Temporizing Matrix to Cadaver Skin in the Reconstruction of Hidradenitis Suppurativa Excisions Not yet recruiting NCT05477225 Phase 4
4 Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa Terminated NCT04582669 Phase 4 Intralesional Triamcinolone 10 mg/mL;Intralesional Triamcinolone 20 mg/mL;Intralesional Triamcinolone 40 mg/mL;Placebo
5 Hidradenitis Suppurativa Patients' Experience of Treatment With Adalimumab Withdrawn NCT04132388 Phase 4 Adalimumab
6 Spironolactone in the Treatment of Hidradenitis Suppurativa: A Prospective, Open-Label Proof-of-Concept and Dose-Ranging Study Withdrawn NCT04100083 Phase 4 Spironolactone 50 MG;Spironolactone 100mg;Spironolactone 200 mg
7 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa Completed NCT04242498 Phase 3 Bimekizumab
8 A Randomized, Double-blind, Multicenter Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNRISE) Completed NCT03713632 Phase 3 Secukinumab;Placebo
9 A Randomized, Double-blind, Multi-center Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNSHINE). Completed NCT03713619 Phase 3 secukinumab;Placebo
10 A Phase 3, Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER (Open-Label Extension) Completed NCT01635764 Phase 3
11 A Phase 3 Multicenter, Open-label, Single Arm Study of the Safety and Efficacy of Adalimumab in Japanese Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT02904902 Phase 3 adalimumab
12 A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER I Completed NCT01468207 Phase 3
13 A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER II Completed NCT01468233 Phase 3
14 A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa Recruiting NCT04179175 Phase 3 secukinumab
15 A Single Center Clinical Trial to Evaluate the Effect of Sclerotherapy on Fistulas and Sinus Tracts in Adult Patients With Hidradenitis Suppurativa Recruiting NCT02805595 Phase 3 23.4% Hypertonic saline;Saline
16 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa Active, not recruiting NCT04242446 Phase 3 Bimekizumab
17 A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa Enrolling by invitation NCT04901195 Phase 3 Bimekizumab
18 Rediscovery of Metformin for the Chronic Disabling Auto-inflammatory Disease Hidradenitis Suppurativa Not yet recruiting NCT04649502 Phase 3
19 A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa Not yet recruiting NCT05620836 Phase 3 Povorcitinib;Placebo
20 A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa Not yet recruiting NCT05620823 Phase 3 Povorcitinib;Placebo
21 To Determine The Efficacy Of A 1320nm Nd: YAG Nonablative Laser For Treatment of Hidradenitis Suppurativa Terminated NCT00367328 Phase 3
22 An Open-label Single Center Study to Evaluate the Efficacy of SILIQ™ (Brodalumab) for the Treatment of Moderate Hidradenitis Suppurativa Unknown status NCT03910803 Phase 2 Brodalumab
23 Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study. The HiGUS-trial Unknown status NCT04061395 Phase 2
24 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Risankizumab in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT03926169 Phase 2 Risankizumab;Placebo for risankizumab
25 A Phase 2 Open-label Single Center Study to Evaluate the Efficacy of Apremilast for the Treatment of Moderate Hidradenitis Suppurativa Completed NCT02695212 Phase 2 Apremilast
26 Open Label,Phase Two Study to Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT00827996 Phase 2 adalimumab
27 An Open Label Phase II Trial to Evaluate the Safety of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa Completed NCT03001622 Phase 2
28 A PHASE 2A, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 16-WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF-06650833, PF-06700841, AND PF-06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA Completed NCT04092452 Phase 2 PF-06650833;PF-06700841;PF-06826647;Placebo
29 Pilot Study of Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa Completed NCT03275870 Phase 1, Phase 2 Hydroxychloroquine
30 Proof of Concept Study on LTX-109 as Treatment for Hidradenitis Suppurativa Completed NCT04756336 Phase 1, Phase 2 LTX-109 gel, 3% w/w
31 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT03852472 Phase 2 Avacopan
32 Randomized, Double-blind, Placebo-controlled, Study of Spesolimab in Patients With Moderate to Severe Hidradenitis Suppurativa Completed NCT04762277 Phase 2 Spesolimab;Placebo
33 A Double-blind, Randomised, Placebo-controlled Clinical Trial of the Efficacy of MABp1, a- First-in-class True Human Antibody Targeting Interleukin-1alpha, in Patients With Hidradenitis Suppurativa Not Eligible for antiTNF Therapy Completed NCT02643654 Phase 2 MABp1;Placebo
34 Phase 2 Study to Assess the Safety and Efficacy of Infliximab for the Treatment of Hidradenitis Suppurativa Completed NCT00795574 Phase 2 infliximab;Placebo Comparator
35 A Prospective Proof of Concept Study to Evaluate the Potential Efficacy of Ustekinumab in Patients With Moderate to Severe Hidradenitis Suppurativa (Acne Ectopica) Completed NCT01704534 Phase 2 Ustekinumab
36 A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients Completed NCT02421172 Phase 2 Placebo
37 A Phase II Open Label Clinical Trial of Etanercept for the Treatment of Hidradenitis Suppurativa Completed NCT00107991 Phase 2 etanercept
38 A Phase 2, Dose-Escalation, Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa Completed NCT03607487 Phase 2 INCB054707;Placebo
39 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT04430855 Phase 2 Upadacitinib;Placebo Upadacitinib
40 A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa Completed NCT04019041 Phase 2 bermekimab;placebo
41 A Phase II, Open Label Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa Completed NCT03512275 Phase 2 Bermekimab Monoclonal Antibody 400 mg
42 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT03628924 Phase 2 Guselkumab dose 1;Guselkumab dose 2;Guselkumab dose 3;Placebo
43 A Phase 2 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa Completed NCT00918255 Phase 2 Placebo
44 A Phase 2 Multicenter, Investigator-Blind, Subject-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT03248531 Phase 2 Bimekizumab;Adalimumab
45 A Phase 2, Open-Label, Single-Arm Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa Completed NCT03569371 Phase 2 INCB054707
46 A Double-blind, Randomized, Placebo-controlled Clinical Trial of the Safety and Efficacy of Anakinra in Patients With Hidradenitis Suppurativa Completed NCT01558375 Phase 2 Water for injection;Anakinra
47 A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT03487276 Phase 2 IFX-1;Placebo
48 An Open Label Non-randomized Study Assessing the Efficacy and Tolerability of Fixed-dose Regimen Daily Subcutaneous Anakinra for the Treatment of Moderate to Severe Hidradenitis Suppurativa Completed NCT01516749 Phase 2 anakinra
49 Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis: A Randomised Double-blind Placebo Controlled Trial Completed NCT03049267 Phase 2 Apremilast;Placebo Oral Tablet
50 A Phase 2 Study of the Safety and Efficacy of Etanercept for the Therapy of Hydradenitis Suppurativa Completed NCT00329823 Phase 2 Etanercept sc 50mg per week for 12 weeks

Search NIH Clinical Center for Hidradenitis Suppurativa

Cochrane evidence based reviews: hidradenitis suppurativa

Genetic Tests for Hidradenitis Suppurativa

Anatomical Context for Hidradenitis Suppurativa

Organs/tissues related to Hidradenitis Suppurativa:

MalaCards : Skin, Liver, Lymph Node, B Cells, Neutrophil, Breast, Thyroid

Publications for Hidradenitis Suppurativa

Articles related to Hidradenitis Suppurativa:

(show top 50) (show all 3826)
# Title Authors PMID Year
1
Citation analysis of the 100 top-cited articles on the topic of hidradenitis suppurativa since 2013 using Sankey diagrams: Bibliometric analysis. 62 41
36343026 2022
2
Bone Metabolism in Patients with Hidradenitis Suppurativa: A Case-control Study. 62 41
36444563 2022
3
Serum Immunoglobulin G Is a Marker of Hidradenitis Suppurativa Disease Severity. 62 41
36430277 2022
4
Impact of etiology leading to abdominoperineal resection with anterolateral thigh flap reconstruction: A retrospective cohort study. 62
36112361 2023
5
Hidradenitis suppurativa: racial and socioeconomic considerations in management. 62
35333408 2022
6
Menopause, skin and common dermatoses. Part 2: skin disorders. 62
35727900 2022
7
Perspectives of obstetricians/gynecologists on hidradenitis suppurativa care: a survey study. 62
36419800 2022
8
Fast-growing mass in a patient with hidradenitis suppurativa. 62
35470548 2022
9
Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study. 62
35934210 2022
10
Exploring the role of systemic immune-inflammation index and neutrophil-lymphocyte ratio in cardiovascular risk stratification for patients with hidradenitis suppurativa: A cross-sectional study. 62
36000267 2022
11
Low predictive value of questionnaire-based diagnosis of hidradenitis suppurativa. 62
35870150 2022
12
Neighborhood-based analysis of adolescent hidradenitis suppurativa prevalence in a large metropolitan area. 62
36248206 2022
13
Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project. 62
36056741 2022
14
Drug survival of Adalimumab biosimilar vs Adalimumab originator in Hidradenitis Suppurativa: can equivalence be assumed? A retrospective cohort study. 62
36461770 2022
15
Patient perspectives on diagnosis and management of hidradenitis suppurativa: A web-based survey. 62
36311912 2022
16
Pain measurement in painful skin conditions and rheumatoid arthritis randomized controlled trials: a scoping review to inform pain measurement in hidradenitis suppurativa. 62
35962565 2022
17
A survey of dermatologist perspectives on disease management of patients with hidradenitis suppurativa. 62
36237848 2022
18
Association of hidradenitis suppurativa and liver disease: A systematic review and meta-analysis. 62
36248209 2022
19
Effects of mixed-technology CO2 and Ga-As laser in patients with hidradenitis suppurativa-A case series. 62
36457941 2022
20
Adalimumab therapy is associated with increased faecal short chain fatty acids in hidradenitis suppurativa. 62
36054650 2022
21
Novel Regimen of IL-17A Inhibitor Secukinumab for the Remission of Severe Hidradenitis Suppurativa: Case Report. 62
36468954 2022
22
A review of how pain is measured in painful skin conditions and rheumatoid arthritis studies, to determine pain measurement in future hidradenitis suppurativa trials. 62
36464931 2022
23
Human skin microbiota in health and disease: The cutaneous communities' interplay in equilibrium and dysbiosis: The cutaneous communities' interplay in equilibrium and dysbiosis. 62
34919288 2022
24
This Month in JAAD Case Reports: December 2022. Hidradenitis suppurative and malignancy. 62
36152695 2022
25
Evolving utility of apremilast in dermatological disorders for off-label indications. 62
35974705 2022
26
Self-disgust in Patients with Dermatological Diseases. 62
35113320 2022
27
Interpretation of comorbidity risk in hidradenitis suppurativa: comparing odds ratio and 'number needed to be exposed'. 62
35793407 2022
28
Patterns of Surgical Recurrence in Patients with Hidradenitis Suppurativa. 62
36470224 2022
29
Epigenetic Dysregulation in Autoimmune and Inflammatory Skin Diseases. 62
36346551 2022
30
Severe atopic dermatitis and concurrent severe hidradenitis suppurativa successfully treated with dupilumab. 62
36006169 2022
31
Variations in genetics, biology, and phenotype of cutaneous disorders in skin of color. Part II: Differences in clinical presentation and disparities in cutaneous disorders in skin of color. 62
35817332 2022
32
Variations in genetics, biology, and phenotype of cutaneous disorders in skin of color - Part I: Genetic, biologic, and structural differences in skin of color. 62
35809800 2022
33
Systemic AA amyloidosis in hidradenitis suppurativa: Should we be screening? 62
36463423 2022
34
Effect of hidradenitis suppurativa on obstetric and neonatal outcomes. 62
35135394 2022
35
Stress signalling and STAT1 activation characterize the keratinocytic gene expression pattern in Hidradenitis suppurativa. 62
35881108 2022
36
Clostridium difficile infection risk in patients with hidradenitis suppurativa. 62
35700148 2022
37
Potential use of microwave technology in dermatology. 62
35699665 2022
38
Management of patients with hidradenitis suppurativa during COVID-19 vaccination: an experience from southern Italy. Comment on: 'Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa'. 62
35727206 2022
39
Methylated miRNAs may serve as potential biomarkers and therapeutic targets for hidradenitis suppurativa. 62
35921387 2022
40
Hidradenitis suppurativa and inflammatory bowel disease in a nested case-control study. 62
36371384 2022
41
The Skin and Gut Microbiome in Hidradenitis Suppurativa: Current Understanding and Future Considerations for Research and Treatment. 62
36116091 2022
42
Comorbid diseases of hidradenitis suppurativa: a 15-year population-based study in Olmsted County, Minnesota, USA. 62
35485975 2022
43
The impact of hidradenitis suppurativa on quality of life is worse than inflammatory bowel disease and myocardial infarction. 62
35932467 2022
44
Hyperthyroidism and hypothyroidism in patients with hidradenitis suppurativa: a systematic review and meta-analysis. 62
36331091 2022
45
Psoriasis and hidradenitis suppurativa are associated with inflammatory bowel disease: a growing body of evidence. 62
35975655 2022
46
Occurrence of inflammatory bowel disease in patients with chronic inflammatory skin diseases: a cohort study: Classification: Epidemiology. 62
35718888 2022
47
Modulation of keratin deposition and pathogenesis of hidradenitis suppurativa: evidence coming from pachyonychia congenita. 62
35996837 2022
48
Massive squamous cell carcinoma arising from hidradenitis suppurativa with marked hypercalcemia and neutrophilia. 62
36186407 2022
49
Concurrent Interstitial Granulomatous Dermatitis and TNF-α Antagonist-Induced Lupus Syndrome Secondary to Adalimumab for Crohn's Disease. 62
36342727 2022
50
Defining patient-centered research priorities in pediatric dermatology. 62
36443263 2022

Variations for Hidradenitis Suppurativa

Expression for Hidradenitis Suppurativa

Search GEO for disease gene expression data for Hidradenitis Suppurativa.

Pathways for Hidradenitis Suppurativa

Pathways related to Hidradenitis Suppurativa according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.82 TNF PSENEN PSEN1 NCSTN IL26 IL23A
2
Show member pathways
13.8 PSTPIP1 PSENEN PSEN1 NOD2 NLRP3 NCSTN
3
Show member pathways
13.62 TNF IL26 IL23A IL1B IL1A IL17A
4
Show member pathways
13.54 TNF IL26 IL23A IL1B IL1A IL17A
5
Show member pathways
13.4 TNF IL26 IL23A IL1B IL1A IL17A
6
Show member pathways
13.3 TNF IL26 IL23A IL1B IL1A IL17A
7
Show member pathways
13.21 TNF NOD2 LCN2 IL26 IL23A IL1B
8
Show member pathways
13.13 TNF S100A7 PSTPIP1 PSEN1 NOD2 NLRP3
9
Show member pathways
12.84 TNF PSENEN PSEN1 NCSTN IL1B IL1A
10
Show member pathways
12.64 TNF IL1B IL1A IL17A IL12RB1 IFNG
11
Show member pathways
12.59 TNF IL23A IL1B IL17A IL12RB1 IFNG
12
Show member pathways
12.51 TNF NOD2 NLRP3 IL1B
13
Show member pathways
12.41 TNF IL1B IL1A IFNG
14
Show member pathways
12.31 TNF IL1B IL1A IFNG
15
Show member pathways
12.16 IFNG IL12RB1 IL17A IL23A TNF
16 12.11 TNF IL1B IL1A IFNG
17
Show member pathways
12.02 PSENEN PSEN1 NCSTN IL1A
18 12 TNF IL1B IL1A IFNG
19
Show member pathways
11.94 PSTPIP1 NLRP3 MEFV IL1B IL1A
20
Show member pathways
11.91 TNF IL1B IL17A IL12RB1 IFNG
21 11.91 TNF LCN2 IL23A IL1B IL1A IL17A
22
Show member pathways
11.9 PSTPIP1 NOD2 NLRP3 MEFV
23
Show member pathways
11.86 IL23A IL17A IL12RB1
24 11.86 TNF IL1B IL1A IL17A IFNG
25
Show member pathways
11.82 TNF NLRP3 IL1B IFNG
26
Show member pathways
11.8 IL26 IL23A IL1B IL17A IL12RB1 IFNG
27 11.78 TNF IL23A IL1B IFNG
28
Show member pathways
11.75 PSENEN PSEN1 NCSTN
29 11.74 IL23A IL1B IL17A IFNG
30 11.73 CRP IFNG TNF
31
Show member pathways
11.7 PSENEN PSEN1 NCSTN
32
Show member pathways
11.69 TNF IL1B IL1A IFNG
33 11.66 TNF LCN2 IL1A
34 11.66 TNF IL1B IL1A
35 11.66 PSENEN PSEN1 NCSTN
36 11.64 IFNG IL12RB1 IL17A IL1B IL23A TNF
37 11.57 TNF NOD2 IFNG CAMP
38 11.54 TNF IL1B IFNG
39 11.52 TNF IL1B IL1A
40 11.51 PSENEN PSEN1 NCSTN
41 11.5 TNF IL1B IL1A IFNG
42 11.45 NOD2 NLRP3 MEFV IL1B
43 11.38 TNF IL1B IL1A
44 11.24 IFNG IL1A IL1B TNF
45 11.22 TNF IL23A IL1B IL17A IFNG
46
Show member pathways
11.2 TNF NOD2 IL23A IL1A IL12RB1 IFNG
47 11.19 NLRP3 IL1B IFNG
48 11.19 TNF IL23A IL17A IFNG
49 11.17 NCSTN PSEN1 PSENEN
50 11.09 PSENEN PSEN1 NCSTN

GO Terms for Hidradenitis Suppurativa

Cellular components related to Hidradenitis Suppurativa according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.18 TNF S100A7 LCN2 IL26 IL23A IL1B
2 extracellular region GO:0005576 10.02 CAMP CRP IFNG IL17A IL1A IL1B
3 obsolete integral component of presynaptic membrane GO:0099056 9.43 PSENEN PSEN1 NCSTN
4 gamma-secretase complex GO:0070765 9.1 PSENEN PSEN1 NCSTN

Biological processes related to Hidradenitis Suppurativa according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.49 TNF PSEN1 IL1B IL1A IFNG CRP
2 apoptotic process GO:0006915 10.42 IFNG IL17A IL1A IL1B LCN2 NLRP3
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.38 TNF S100A7 NOD2 IL26 IL1A
4 immune response GO:0006955 10.35 TNF IL23A IL1B IL1A IL17A IFNG
5 Notch signaling pathway GO:0007219 10.29 PSENEN PSEN1 NCSTN IL17A
6 positive regulation of JNK cascade GO:0046330 10.27 TNF NOD2 IL1B IL1A
7 cellular response to lipopolysaccharide GO:0071222 10.26 TNF NOD2 NLRP3 IL1B IL1A CAMP
8 defense response to Gram-negative bacterium GO:0050829 10.25 S100A7 IL23A IL17A CAMP
9 positive regulation of MAP kinase activity GO:0043406 10.24 TNF PSEN1 NOD2 IL1B
10 positive regulation of type II interferon production GO:0032729 10.23 TNF IL23A IL1B IL12RB1
11 innate immune response GO:0045087 10.23 CAMP CRP IL17A IL23A LCN2 MEFV
12 positive regulation of NIK/NF-kappaB signaling GO:1901224 10.22 TNF NOD2 IL23A IL1B
13 regulation of insulin secretion GO:0050796 10.19 TNF IL1B IFNG
14 positive regulation of phagocytosis GO:0050766 10.19 TNF NOD2 IL1B IFNG
15 positive regulation of nitric oxide biosynthetic process GO:0045429 10.18 TNF IL1B IFNG
16 immune system process GO:0002376 10.17 PSTPIP1 NOD2 MEFV LCN2 IL23A IL17A
17 positive regulation of interleukin-12 production GO:0032735 10.17 NOD2 IL23A IL17A IFNG
18 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 10.16 IL1A IL1B TNF
19 positive regulation of cytokine production GO:0001819 10.16 TNF IL26 IL1B IL1A IFNG
20 positive regulation of catalytic activity GO:0043085 10.15 NCSTN PSEN1 PSENEN
21 positive regulation of mitotic nuclear division GO:0045840 10.15 IL1A IL1B TNF
22 response to lipopolysaccharide GO:0032496 10.15 GJB2 IL1A IL1B NOD2 S100A7 TNF
23 positive regulation of tumor necrosis factor production GO:0032760 10.15 IFNG IL17A IL1A IL23A NOD2 PSEN1
24 positive regulation of cytokine production involved in inflammatory response GO:1900017 10.14 IL17A NOD2 TNF
25 positive regulation of inflammatory response GO:0050729 10.13 IFNG IL1B IL23A MEFV NLRP3 TNF
26 membrane protein ectodomain proteolysis GO:0006509 10.12 PSENEN PSEN1 NCSTN
27 inflammatory response GO:0006954 10.11 CRP IL17A IL1A IL1B IL23A MEFV
28 positive regulation of chemokine production GO:0032722 10.1 TNF IL1B IFNG
29 positive regulation of interleukin-6 production GO:0032755 10.1 TNF NOD2 IL1B IL1A IL17A IFNG
30 defense response GO:0006952 10.09 TNF NOD2 NLRP3 CAMP
31 positive regulation of membrane protein ectodomain proteolysis GO:0051044 10.09 TNF IL1B IFNG
32 amyloid precursor protein catabolic process GO:0042987 10.08 PSENEN PSEN1 NCSTN
33 positive regulation of osteoclast differentiation GO:0045672 10.08 TNF IL23A IL17A IFNG
34 amyloid precursor protein metabolic process GO:0042982 10.05 NCSTN PSEN1 PSENEN
35 positive regulation of stress-activated MAPK cascade GO:0032874 10.03 NOD2 IL26 IL1A
36 amyloid-beta formation GO:0034205 10.03 PSENEN PSEN1 NCSTN
37 Notch receptor processing GO:0007220 10.02 PSENEN PSEN1 NCSTN
38 positive regulation of type 2 immune response GO:0002830 10.01 NLRP3 NOD2
39 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 10.01 NOD2 TNF
40 positive regulation of immature T cell proliferation in thymus GO:0033092 10.01 IL1A IL1B
41 astrocyte activation GO:0048143 10.01 TNF PSEN1 IL1B IFNG
42 positive regulation of fever generation GO:0031622 10 IL1B TNF
43 positive regulation of T-helper 17 cell lineage commitment GO:2000330 9.99 IL23A IL12RB1
44 pattern recognition receptor signaling pathway GO:0002221 9.99 NOD2 NLRP3 MEFV
45 sequestering of triglyceride GO:0030730 9.98 TNF IL1B
46 positive regulation of nitrogen compound metabolic process GO:0051173 9.97 TNF IFNG
47 fever generation GO:0001660 9.96 IL1B IL1A
48 positive regulation of vitamin D biosynthetic process GO:0060557 9.94 IFNG TNF
49 cellular response to peptidoglycan GO:0071224 9.93 CAMP NLRP3 NOD2
50 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.93 TNF IL1B IFNG

Molecular functions related to Hidradenitis Suppurativa according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.47 TNF IL26 IL23A IL1B IL1A IL17A

Sources for Hidradenitis Suppurativa

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....